Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,232.00
(
0.41%
)
Dow Jones
46,993.26
(
0.00%
)
Brent Oil
101.33
(
0.67%
)
Bitcoin
73,040.62
(
-1.22%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 90683

Thursday, 03/25/2010 8:42:22 PM

Thursday, March 25, 2010 8:42:22 PM

Post# of 257253
BIIB/ELN started an RRMS “switching” study of Tysabri vs Copaxone or Rebif. (See #msg-46709942 and #msg-39971611 for background on where these drugs stand commercially.)

clinicaltrials.gov entry:
http://clinicaltrials.gov/ct2/show/NCT01058005

Today’s press release:
http://finance.yahoo.com/news/Biogen-Idec-and-Elan-Enroll-bw-434267012.html?x=0&.v=1


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now